cyclophosphamide,fludarabine,lisocabtagene maraleucel
bms
['transcend,(-nhl-001),(-nhl 001),(-nhl001),(-nhl-006),(-nhl 006),(-nhl006),(-pilot-017006),(-pilot017006),(-pilot 017006)', 'transcend fl', 'lymphoma', 'follicular', 'bms', 'scienceatbms']
patients with follicular #lymphoma (fl), whose disease progresses after multiple lines of therapy, have poor outcomes and limited therapy options. at #17icml, we shared data from our transcend fl study, reinforcing our commitment to patients with relapsed or refractory fl.
Official Bristol Myers Squibb Twitter handle for science. Connecting researchers, scientists and healthcare professionals through science; guidelines below: